v3.25.1
Liquidity, Significant Risks and Uncertainties (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended
Nov. 29, 2024
Mar. 31, 2025
Mar. 31, 2024
May 02, 2025
Product Information [Line Items]        
Net losses   $ 3,855 $ 3,506  
Net cash used in operating activities   4,400 $ 2,600  
Marketable securities   $ 8,000    
Shares issued, offering price $ 20,000      
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Department of Veterans Affairs and Department of Defense [Member]        
Product Information [Line Items]        
Concentration risk percentage   70.30% 71.20%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Department of Veterans Affairs and Department of Defense [Member] | No Single Facility [Member]        
Product Information [Line Items]        
Concentration risk percentage   10.00%    
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Department of Veterans Affairs and Department of Defense [Member] | One Facility [Member]        
Product Information [Line Items]        
Concentration risk percentage     10.00%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | United Kingdom National Health Service [Member] | One Facility [Member]        
Product Information [Line Items]        
Concentration risk percentage   10.00% 10.00%  
Revenue Benchmark [Member] | Government Contracts Concentration Risk [Member] | Department of Veterans Affairs and Department of Defense [Member] | Lovell [Member]        
Product Information [Line Items]        
Concentration risk percentage   10.00% 10.00%  
Securities Purchase Agreement [Member]        
Product Information [Line Items]        
Aggregate proceeds   $ 200    
Sales Agreement [Member] | Subsequent Event [Member]        
Product Information [Line Items]        
Remaining shares available for issuance       $ 19,800